PRESENTATION

Q1 2022 — Presentation

Q1 2022PDF · 31 pages2.4 MB
Merck
Q1 2022 Earnings
April 28, 2022

-- 1 of 31 --

Agenda
2
Strategy and
Business Update
Rob Davis
President & Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 31 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
3
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will
receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

-- 3 of 31 --

Strategy &
Business Update
Rob Davis
President & Chief Executive Officer

-- 4 of 31 --

Delivered on our key strategic priorities Q1
5
Achieved strong commercial and
financial performance
Advanced the pipeline to meet patient
unmet need
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 31 --

Merck achieved excellent Q1 financial performance 1
6
WORLDWIDE SALES 1
$15.9B+50% growth
Ex-LAGEVRIO, +19% growth
NON-GAAP EPS
$2.14+84% growth
Merck
1. Results from continuing operations attributable to Merck & Co., Inc.

-- 6 of 31 --

Expect continued strong growth in revenues and earnings
7
1. Beginning in 2022, Merck will no longer exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets
obtained in transactions accounted for as asset acquisitions from its non-GAAP results. For 2020, non-GAAP results have been recast to include $4.2 billion of incremental R&D expenses,
which reduced EPS by $1.56. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D expense, which reduced EPS by $0.65. 2. Non-GAAP operating margins.
Revenue growth
Delivering visible de-risked
revenue growth through 2025
Operating margin expansion
Commitment to drive leverage in
the P&L with operating margins2
>43% by 2025
2020 	2021 	2022
$41.5B
+6%
$48.7B
+17%
2020 	2021 	2022
$2.97
$5.37
Revenue
Non-GAAP EPS1
GUIDANCE
RANGE
$56.9B-$58.1B
GUIDANCE
RANGE
$7.24-$7.36
Longer term…

-- 7 of 31 --

Multiple levers to navigate the KEYTRUDA LOE
8
• 	Leverage leadership in oncology
• 	Enhance durable growth drivers
• 	Deploy cash flow from key assets
to business development
• 	Advance pipeline across key
therapeutic areas
Shorten period
to return to
strong growth
Minimize
the LOE
gap
Chart not to scale.
Time
Revenue

-- 8 of 31 --

Increasing transparency into our business
9
Cardiovascular event 	ESG event
• 	Highlighted broad and growing cardiovascular
pipeline and portfolio
• 	Eight potential approvals across cardiovascular
pipeline expected by 2030
• 	Highlighted our ESG priority areas and outlined our
long-term strategy
• 	ESG approach grounded in Merck’s core values

-- 9 of 31 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 10 of 31 --

Strong Q1 sales growth across Human Health and Animal Health
11
Merck
WORLDWIDE SALES1,2,3
$15.9B+ 50% growth
+19% ex-LAGEVRIO 4
+21% ex-exchange, ex-LAGEVRIO 5
$14.1B
+53% growth
+18% ex-LAGEVRIO4
+21% ex-exchange, ex-LAGEVRIO5
Human Health 3
$1.5B
+4% growth
+9% ex-exchange
Animal Health
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. In 1Q 2021 human health had ~$500M of negative
pandemic impact 4. Excludes LAGEVRIO sales of $3.2 billion in the quarter 5. Excludes LAGEVRIO sales of $3.2 billion in the quarter and foreign exchange

-- 11 of 31 --

Oncology: KEYTRUDA drives continued momentum
12	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $4.8B increased 27%
year-over-year, driven by momentum across
key tumor types and recent launches
– In the U.S., sales of $2.8B driven by growth across
key tumor types, including continued leadership in
lung, as well as recent earlier-stage cancer
launches in TNBC, RCC and melanoma
– Ex-U.S., 26% growth was driven by global uptake
in lung as well as HNSCC and RCC
• KEYTRUDA will continue to expand into earlier
lines of therapy
– KEYTRUDA is approved in 5 early-stage cancers
– More than half of KEYTRUDA’s growth will come
from indications in earlier-stage treatment
settings through 2025, and will represent
approximately 25% of total KEYTRUDA revenue 1Q20 	1Q21 	1Q22
$3.9B
+16%
$3.3B
+46%
$4.8B
+27%

-- 12 of 31 --

Oncology: Strong growth across broad portfolio
• Lynparza sales increased 20%, with growth
driven by continued uptake in metastatic
breast cancer
– Opportunity in early-stage breast following
OlympiA approval
– Potential to expand further in metastatic
castration-resistant prostate based on
encouraging PROpel trial results
• Lenvima growth driven largely by recent
launches in RCC and endometrial as well as
HCC in China and certain one-time items
• WELIREG launching successfully in patients
with certain VHL-associated tumors
– Potential to expand to broader RCC indications in
the future
1Q20 	1Q21 	1Q22
$228M
+51%
$145M
+86%
$266M
+20%
1Q20 	1Q21 	1Q22
$130M
-1%
$128M
+73%
$227M
+77%
13	Increase/decrease in sales exclude the impact of foreign exchange.

-- 13 of 31 --

Vaccines: GARDASIL growth reflects robust demand and improved supply
14
• GARDASIL sales of $1.5B increased 60% year-
over-year driven by strong demand outside
the U.S. and increased supply
– Ex-U.S., growth was driven by robust demand,
particularly in China, and increased supply
– U.S. sales increased due to timing of CDC
purchases
Increase/decrease in sales exclude the impact of foreign exchange.
1Q20 	1Q21 	1Q22
$917M
-20%
$1.1B
+33%
$1.5B
+60%

-- 14 of 31 --

Hospital: Strong global demand across products
15
• BRIDION sales of $395M increased 20%
primarily due to the ongoing recovery in
surgical procedures
• PREVYMIS sales grew 20%, driven by
continued strong global demand
• ZERBAXA continued restocking and uptake
following initiation of resupply in Q4 2021
Growth rates exclude the impact of foreign exchange.
1Q20 	1Q21 	1Q22
$340M
+11%$299M
+19%
$395M
+20%
1Q20 	1Q21 	1Q22
$82M
+31%	$60M
+90%
$94M
+20%

-- 15 of 31 --

Animal Health: durable growth across portfolio
16
• Animal Health sales increased 9% to $1.5B,
reflecting growth across geographies and
segments
– Companion Animal sales grew 13%, driven by the
BRAVECTO parasiticide line of products and
vaccines
– Livestock sales increased 7% reflecting higher
demand globally for ruminants and poultry
products
Growth rates exclude the impact of foreign exchange.
1Q20 	1Q21 	1Q22
$1.4B
+15%
$1.2B
+21%
$1.5B
+9%

-- 16 of 31 --

Q1 2022 continuing operations non-GAAP financial results summary:
Delivered strong revenue and EPS growth
Q1 2022 	Q1 2021 	Change Change
Ex-FX
Sales 	$15.9 	$10.6 	+50% 	+52%
Non-GAAP Gross
Margin 70.7% 	76.6% 	-5.9pts 	-5.7pts
Non-GAAP Operating
Expenses $4.8 	$4.6 	+5% 	+7%
Non-GAAP Tax Rate 	14.0% 	14.3% 	-0.3pts 	N/A
Non-GAAP EPS that
excludes certain items $2.14 	$1.16 	+84% 	+89%
$ in billions, except EPS amounts
17
Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses
Non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived
in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. See 1Q22 earnings
release for GAAP to non-reconciliation.

-- 17 of 31 --

Merck updated full-year 2022 guidance
1. GAAP Gross Margin Rate: ~68%. 2. GAAP Operating Expenses: $20.5 to $21.5 billion. 3. GAAP Tax Rate: ~12.5% - 13.5% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q1
2022 earnings release 5. Beginning in 2022, Merck will no longer exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges
related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Prior periods have been recast to reflect this change
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $56.1B to $57.6B
+15% to +18% (+17% to +20% ex-FX)
$56.9B to $58.1B
+17% to +19% (+19% to +21% ex-FX)
• 	+11% to +12% excluding LAGEVRIO and the
impact from foreign exchange
• 	Includes $5-5.5 billion of LAGEVRIO revenue
• 	Assumes ~2% negative FX impact
o Includes an incremental $200M headwind
Non-GAAP
Gross Margin Rate 1 	~74.0% 	74.0% - 74.5%
Non-GAAP
Operating Expenses2 	Increase by mid-to-high single-digit rate 	$20.3B to $21.3B • 	Consistent with the midpoint implied by our prior
guidance
Other (Income) / Expense 	~$350M of expense 	~$350M of expense
Tax Rate3 	~13.0-14.0% 	~13.5-14.5% • 	Reflects an increase in estimated U.S. taxes to be
paid on foreign income
Shares Outstanding 	~2.53B 	~2.53B
GAAP EPS 	$5.76 to $5.91 	$5.90 to $6.02
Non-GAAP EPS4,5 	$7.12 to $7.27 	$7.24 to $7.36 • 	Now assumes ~2% negative FX impact (vs. prior
~1% negative FX impact)
18

-- 18 of 31 --

Key modeling assumptions & outlook
19
LAGEVRIO 	Other Revenue	GARDASIL 	Financial Reporting
• 	Updated full year
guidance of $5.0B to
$5.5B
• 	Delivered ~6.4M of
~10M courses
committed from supply
and purchase
agreements through Q1;
expect approximately
half of the remaining
full-year revenue from
LAGEVRIO in the second
quarter
• 	Reflects ongoing supply
sales to Organon as well
as to Johnson & Johnson
for its COVID vaccine
• 	Reflects revenue hedge
and royalties
• 	Received ~$100M of
payments related to
out-licensing
agreements in Q1
• 	Non-GAAP results will
no longer exclude
charges related to
expenses for upfront
and milestone payments
related to collaborations
and licensing
agreements, or charges
related to pre-approval
assets obtained in
transactions accounted
for as asset acquisitions
• 	Expect very strong
growth in 2022,
particularly ex-U.S.,
driven by robust demand
and increased supply
• 	Full year sales growth not
anticipated to be at the
same pace as 2021

-- 19 of 31 --

20
Well positioned balance
sheet with capacity to
fund additional
value-enhancing
business development
opportunities
$2.2
$1.0
$1.7
$0.8
$0.0
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions1
Capital allocation order of priority
1. Reflects Q1 spend
Remain committed to balanced capital allocation strategy

-- 20 of 31 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 21 of 31 --

Driving value for patients and shareholders by progressing our pipeline
22
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the U.S., received FDA approval for
Lynparza for adjuvant treatment of adults
with gBRCAm, HER2-negative high-risk early
breast cancer based on OlympiA and for
KEYTRUDA in advanced endometrial cancer
that is MSI-H or dMMR deficient based on
KN-158 (Cohorts D & K)
• 	In the EU, received positive CHMP opinions
for certain MSI-H tumors based on KN-158
and KN-164, recurrent or metastatic cervical
cancer in certain patients based on KN-826
and neoadjuvant / adjuvant treatment for
locally advanced or early stage TNBC based
on KN-522
• 	In Japan, received approval for KEYTRUDA +
Lenvima RCC based on KN-581 and
KEYTRUDA approved for previously treated
TMB-H based on KN-158
• 	Presented data at ESMO Virtual Plenary for KN-
091 and OlympiA, at ASCO GU for PROpel and
at AACR for vibostolimab+pembrolizumab for
the first time in ovarian and cervical cancers
• 	Presented data from the Phase 3 MOVe-OUT
trial studying LAGEVRIO (molnupiravir) at
ECCMID
• 	Following approval for KEYTRUDA as adjuvant
treatment for melanoma (stage IIB and IIC)
based on KEYNOTE-716, announced the study
met its secondary endpoint of DMFS (distant
metastasis-free survival)
• 	Announced breakthrough therapy designation
for V116 and plans to move to Phase 3 clinical
development
• 	Completed enrollment for the Phase 3 STELLAR
trial studying sotatercept in PAH
• 	Presented real-world observational studies
providing additional evidence of effectiveness of
PREVYMIS in preventing CMV in adults
undergoing allogeneic HCT

-- 22 of 31 --

Continuing to expand, deepen and extend in oncology
23
Prostate cancer	Earlier-stage 	Global highlights	Women’s cancers
• 	Broadest IO clinical
development program
• 	Six FDA approvals in
oncology
‒ 	Received approval
for early-stage
breast cancer for
Lynparza based on
OlympiA
‒ 	Following approval in
adjuvant melanoma,
KN-716, met key
secondary endpoint
of DMFS
• 	Expansive program
across multiple tumors
• 	Received fourth FDA
approval in gynecologic
cancers for KEYTRUDA
• 	Marks fifth FDA
approval based on
innovative trial design
of KN-158
• 	Robust Phase 3 program
‒ 	PROpel: Lynparza
+ abiraterone
reduced the risk of
disease progression
or death by 34% in
mCRPC
‒ 	KN-921: KEYTRUDA
+ docetaxel in mCRPC
‒ 	KN-641: KEYTRUDA
+ enzalutamide in
mCRPC
• 	Positive CHMP opinions:
‒ 	Cervical cancer based
on KN-826
‒ 	MSI-H or dMMR
tumors in five cancer
types based on
KN-158 and KN-164
‒ 	Neoadjuvant /
adjuvant treatment
for locally advanced or
early stage TNBC
based on KN-522
• 	Approval for renal cell
carcinoma based on
KN-581 in Japan

-- 23 of 31 --

Cardiovascular portfolio well positioned for growth
24
Verquvo
HFrEF
Stable HF
Sotatercept
PAH
Multiple
Indications
MK-5475
PAH
Multiple
Indications
Potential
Approvals
Approved
Verquvo
HFrEF
post HFH
Adempas
PAH/CTEPH
MK-0616
Hyper-
cholesterolemia
MK-2060
Thrombosis
ESRD
Eight potential approvals
across cardiovascular
pipeline expected by 2030
• 	Completed enrollment for
the STELLAR trial,
evaluating sotatercept in
PAH, ahead of schedule
• 	Verquvo included in the
2022 AHA, ACC and HFSA
guideline as a level 2b
recommendation
• 	Ongoing VICTOR study
designed to broaden
opportunity for Verquvo

-- 24 of 31 --

LAGEVRIO represents an important treatment option
against COVID-19 in high-risk, non-hospitalized patients
25
• 	Pandemic continues to evolve with regional
surges
• 	Recent variants appear to be resistant to
specific monoclonal antibody regimens and
able to evade vaccine protection
• 	Accessible therapeutic options are needed
for appropriate high-risk patients
• 	LAGEVRIO is well-positioned to play a role
due to its key attributes:
– Oral treatment option
– Low propensity for drug-drug interactions
– High barrier to resistance

-- 25 of 31 --

Pipeline updates and progress
26
Population-specific pneumococcal vaccine development program
• 	Sequence of
VAXNEUVANCE and
PNEUMOVAX 23 is an
option recommended by
CDC for adults 65+, and
for adults 19 to 64 with
certain underlying
medical conditions or
other risk factors
• 	Sequence offers patients
a strong immune
response together with
the broadest serotype
coverage
• 	Received Breakthrough
Therapy Designation
by the FDA
• 	Designed to target
serotypes responsible
for ~85% of residual
disease in the adult 65+
population1
• 	Full results from the
Phase 1/2 trial studying
V116 to be presented at
ISPPD in June 2022
• 	Planning to enter
Phase 3 in 2022
• 	Under review by the
FDA [PDUFA: July 1]
• 	Provided requested
analyses to the FDA; no
additional studies
requested
• 	Potential to maintain
existing protection and
prevent additional
disease
V116
adults
VAXNEUVANCE
adults
V117
pediatrics
VAXNEUVANCE
pediatrics
• 	Targeted approach to
pediatric development
in Phase 1 clinical
development
1. Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Core surveillance (ABCs).

-- 26 of 31 --

Q&A
Rob Davis
President & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 27 of 31 --

Appendix
28

-- 28 of 31 --

Q1 2022 continuing operations GAAP financial results summary
29
Q1 2022 	Q1 2021 	Change Change
Ex-FX
Sales 	$15.9 	$10.6 	+50% 	+52%
Operating Expenses 	$4.9 	$4.6 	+7% 	+8%
Tax Rate 	11.4% 	8.0% 	+3.4pts 	N/A
GAAP EPS 	$1.70 	$1.08 	+57% 	+62%
$ in billions, except EPS amounts

-- 29 of 31 --

$9.1
$4.3
$6.7
$14.5
$0.8
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$20B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.72 $1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022
Dollars per share	
+11% 	+2% 	+2% 	+2% 	+2% 	+2%
+11%
+15%
+7%
Order of priority
Over the past 12 months
Capital investments
2021 to 2025
Commitment to the dividend
30
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%

-- 30 of 31 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V116
Pneumococcal, adult
V184
Chikungunya Virus
Vaccines
Infectious diseases
MK-8189
Schizophrenia
Neuroscience 	Gefapixant (MK-7264)
Cough (US, EU)
CUBICIN (MK-3009)
cSST & Sepsis, pediatric (JPN)
General medicine
General medicine
As of April 28, 2022
V114
Pneumoconjugate Vaccine, adult (JPN),
pediatric (US)
Vaccines
Infectious diseases
Oncology 	Oncology
MK-7075
Overgrowth Syndrome
MK-1942
Treatment Resistant Depression
MK-3655
NASH
MK-6024
NASH
MK-8591B (islatravir+MK-8507) 1
HIV-1 Infection
MK-8591D (islatravir+lenacapavir) 1
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary Tract
cSCC (EU)
Gastric (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
Prostate
SCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-7684A (vibostolimab
+ pembrolizumab)
NSCLC
SCLC
MK-4280A (favezelimab
+ pembrolizumab)
CRC
LENVIMA (MK-7902)
HNSCC
Melanoma
CRC
Esophageal
NSCLC
Gastric
LYNPARZA (MK-7339)
NSCLC
SCLC
CRC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
MK-3475
(pembrolizumab
subcutaneous)
NSCLC
MK-8591A (doravirine+islatravir) 1
HIV-1 Infection
Islatravir (MK-8591) 1
HIV-1 prevention
Molnupiravir (MK-4482)
COVID-19 antiviral
KEYTRUDA (MK-3475)
MSI-H or dMMR Six Tumor Basket (EU)
Adjuvant RCC (JPN)
Adjuvant Melanoma (EU)
High-risk early stage TNBC (EU, JPN)
Cervical (EU, JPN)
2L HCC (US)
LENVIMA (MK-7902)
1L HCC (US)
LYNPARZA (MK-7339)
Prostate cancer (EU)
Adjuvant breast cancer (EU, JPN)
MK-5475
Pulmonary Arterial Hypertension
MK-2060
Cardiovascular
MK-0616
Hypercholesterolemia
Cardiovascular
KEYTRUDA (MK-3475)
Advanced Solid Tumors
LYNPARZA (MK-7339)
Advanced Solid Tumors
MK-6440
(ladiratuzumab vedotin)
Breast
NSCLC
SCLC
HNSCC
Esophageal
Gastric
Prostate
Melanoma
MK-1026 (nemtabrutinib)
Hematological Malignancies
V937
Melanoma
Breast
CSCC
HNSCC
Solid Tumors
MK-4280A
(favezelimab+pembrolizumab)
RCC
SCLC
WELIREG (MK-6482)
Rare Cancers
CRC
Pancreatic
Biliary
HCC
Certain VHL tumors (EU)
MK-4280
(favezelimab)
NSCLC
Hematological Malignancies
LENVIMA (MK-7902)
Biliary
Glioblastoma
Prostate
SCLC
Pancreas
MK-7684A
(vibostolimab+
pembrolizumab)
Biliary
Cervical
Esophageal
Breast
HNSCC
HCC
Endometrial
Prostate
Hematological Malignancies
MK-1308A
(quavonlimab+
pembrolizumab)
Advanced Solid Tumors
HCC
CRC
SCLC
Melanoma
TUKYSA (MK-7119)
Advanced Solid Tumors
CRC
Gastric
Endometrial
NSCLC
Bladder
Biliary
Cervical
MK-7684 (vibostolimab)
Melanoma
MK-2140
Breast
NSCLC
Heme
Solid Tumors
MK-4830
NSCLC
SCLC
RCC
CRC
MK-0482
NSCLC
MK-1308
(quavonlimab)
NSCLC
MK-5890
NSCLC
SCLC
Broad and innovative pipeline to solve significant unmet medical needs
31
Vaccines
MK-1654
Respiratory Syncytial Virus
1. On clinical hold
Sotatercept (MK-7962)
Pulmonary Arterial Hypertension
Cardiovascular
Infectious diseases
Molnupiravir (MK-4482)
COVID-19 antiviral (EU)

-- 31 of 31 --